Increased Disparities in Patients Diagnosed with Metastatic Lung Cancer in the United States Following Lung CT Screening
For a study, the researchers sought to find if the introduction of low-dose computed tomography...
Read More
Oncology
A Multi-Centre Retrospective Analysis of VATS vs Open Lobectomy in Pathological T1 SCLC
VATS, or video-assisted thoracic surgery, was widely employed in the surgical treatment of...
Read More
Second-line tisagenlecleucel does not improve outcomes in B-cell lymphoma
1. Patients with B-cell non-Hodgkin’s lymphoma receiving tisagenlecleucel did not show...
Read More
S-1 plus oxaliplatin noninferior to fluorouracil, leucovorin, and oxaliplatin in perioperative chemotherapy for locally advanced gastric cancer: FOCUS trial
1. This phase 3, randomized controlled trial demonstrated that S-1 plus oxaliplatin (SOX) was...
Read More
Capecitabine maintenance therapy for metastatic nasopharyngeal carcinoma improves progression-free survival
1. Progression-free survival is longer in those treated with capecitabine maintenance therapy as...
Read More
Abemaciclib linked to disease control in patients with p16ink4A-negative mesothelioma
1. Disease control was reported in over half of the patients treated with abemaciclib 2. Most...
Read More
Sintilimab plus anlotinib showed promising clinical and safety response to treat advanced cervical cancer
1. The overall response rate was 54.8% in the intention-to-treat group while it was 59.0% in the...
Read More
Axicabtagene ciloleucel improves event-free survival in relapsed or refractory large B-cell lymphoma
1. Patients with large B-cell lymphoma refractory to first-line therapy receiving axicabtagene...
Read More
Lifestyle Factors & Cancer Survival Prediction Models
There’s abundant evidence that diet and lifestyle factors drive the risk for developing...
Read More
Addition of atezolizumab to capecitabine + bevacizumab is not clinically beneficial in the treatment of refractory metastatic colorectal cancer
1. Atezolizumab plus capecitabine + bevacizumab performed marginally better with regards to...
Read More
Patient-Reported Outcome-Based Symptom Management Vs Usual Care
“Compared with usual care (UC), patient-reported outcome (PRO)-based symptom management can...
Read More
Chemotherapy not associated with an increased COVID-19 mortality risk in active cancer patients
1. This prospective cohort study demonstrated that, in adult patients with active cancer and a...
Read More
Biosimilar drugs undergo rigorous clinical testing and yield comparable outcomes to biologics
1. Cancer biosimilar treatment trials have clinical outcomes that do not differ statistically from...
Read More
Cervical intraepithelial neoplasia grade 3 associated with adverse pregnancy outcomes
1. Compared to population- and sibling-matched cohorts, women previously diagnosed with cervical...
Read More
Olaparib improves the quality of life for metastatic castration-resistant prostate cancer patients
1. Olaparib led to a bigger decrease in pain interference and symptomatic skeletal-related events...
Read More
Trametinib improves progression-free survival among patients with low-grade serous ovarian carcinoma
1. The median progression-free survival for trametinib was significantly greater than that for...
Read More
Pembrolizumab improves survival outcomes in cervical cancer patients
1. Patients receiving pembrolizumab with or without platinum-based chemotherapy experienced longer...
Read More
The religious and spiritual beliefs of cancer patients may influence decision making
1. Overall, the influence of religion and spirituality on treatment decision making was both...
Read More
Venous thromboembolism rates in hospitalized children continue to rise
1. In a large retrospective study, rates of venous thromboembolism (VTE) in pediatric patients...
Read More
Cemiplimab treatment of recurrent cervical cancer is associated with longer overall survival
1. Overall survival is longer in patients treated with cemiplimab as compared to chemotherapy. 2....
Read More